Engineered immune cells take on sarcoma in new combo trial
NCT ID NCT04995003
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new type of immune cell therapy (HER2-CAR T cells) combined with drugs that boost the immune system (pembrolizumab or nivolumab) is safe for people with advanced sarcoma. About 25 participants will receive chemotherapy before the cell infusion to help the therapy work better. Researchers will also study gut bacteria to see if they affect treatment response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas Children's Hospital
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can engineered immune cells tackle childhood sarcoma?
- Can a Patient's own immune cells be engineered to fight a rare sarcoma?
- Can AI read tumor slides to outsmart childhood cancer?
- Can a Patient's own immune cells fight advanced sarcoma?